financetom
Business
financetom
/
Business
/
StandardAero Q2 Likely to Benefit From MRO Demand, RBC Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
StandardAero Q2 Likely to Benefit From MRO Demand, RBC Says
Aug 4, 2025 8:36 AM

11:13 AM EDT, 08/04/2025 (MT Newswires) -- StandardAero ( SARO ) Q2 is poised to benefit from positive industry trends in the maintenance, repair, and overhaul services of engines, RBC Capital Markets said in a report Sunday.

"We can appreciate the capital market overhang on the stock,

but believe the fundamentals remain very attractive," it said.

RBC analysts said they are raising their Q2 organic growth estimate to over 9% as the engine MRO commentary so far has been positive. Its Q2 results are due Aug. 13.

With many other engine aftermarket peers having rerated, the stock could see a positive re-ratings as some investors look for alternatives to play the engine aftermarket, the report said.

RBC kept its outperform rating and $37 price target.

Price: 28.56, Change: +0.70, Percent Change: +2.51

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Lilly forecasts 2025 profit largely above estimates on weight-loss drug strength
Lilly forecasts 2025 profit largely above estimates on weight-loss drug strength
Feb 6, 2025
(Reuters) -Eli Lilly ( LLY ) forecast annual profit largely above Wall Street estimates on Thursday, as it prepares to launch its popular diabetes and weight-loss treatments in new markets. The forecast comes weeks after the drugmaker stunned investors with weaker-than-expected sales for its weight-loss drug Zepbound for the second straight quarter. The profit forecast could be a step towards...
Omnicell's Q4 Adjusted Earnings, Revenue Increase; Provides 2025 Guidance
Omnicell's Q4 Adjusted Earnings, Revenue Increase; Provides 2025 Guidance
Feb 6, 2025
06:47 AM EST, 02/06/2025 (MT Newswires) -- Omnicell ( OMCL ) reported Q4 adjusted earnings Thursday of $0.60 per diluted share, up from $0.33 a year earlier. Analysts polled by FactSet expected $0.58. Revenue for the quarter ended Dec. 31 was $306.9 million compared with $258.8 million a year earlier. Analysts surveyed by FactSet expected $300 million. For Q1, the...
Tapestry raises annual sales forecast
Tapestry raises annual sales forecast
Feb 6, 2025
Feb 6 (Reuters) - Tapestry on Thursday raised its annual sales forecast, betting on strong demand for its pricey Tabby bags and suede boots. The company now expects revenue of about $6.85 billion for the fiscal year 2025, compared with its prior target of more than $6.75 billion. Analysts on average estimated revenue of 6.76 billion, according to data compiled...
Kenvue sees 2025 profit below estimates as strong dollar, weak cough product sales hit
Kenvue sees 2025 profit below estimates as strong dollar, weak cough product sales hit
Feb 6, 2025
(Reuters) - Consumer health company Kenvue ( KVUE ) forecast 2025 adjusted profit below Wall Street estimates on Thursday, hit by a stronger dollar and weak demand for its cough and cold products that include Tylenol and Benadryl. The company, which was spun off from Johnson & Johnson in 2023, has been under pressure from activist Starboard Value to improve...
Copyright 2023-2026 - www.financetom.com All Rights Reserved